FDA Inspection
Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc. – FDA Inspection, Jan 30, 2013
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Pharmaceuticals, Inc., with an inspection on January 30, 2013, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- January 30, 2013
- Product Type
- Drugs
View Company Profile
ID · ef5fade2-c552-4735-a717-6a6b493c9860
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 816303
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
FDA Citations
1- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Boehringer Ingelheim Pharmaceuticals, Inc.
19| Date | Classification | Office | Project area |
|---|---|---|---|
| August 25, 2026 | Not classified | New England District Office | |
| September 11, 2025 | VAI | New England District Office | Bioresearch Monitoring: Human Drugs |
| May 2, 2024 | Not classified | New England District Office | |
| September 22, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| December 12, 2019 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Boehringer Ingelheim Pharmaceuticals, Inc.
- FDA Inspection 1334848 - 2026-08-25
- FDA Inspection 1281125 - 2025-09-11
- FDA Inspection 1235545 - 2024-05-02
- FDA Inspection 1219707 - 2023-09-22
- FDA Inspection 1112627 - 2019-12-12
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.